Search results
Pfizer Stock Rises as Outlook Raised After Earnings Beat
Barrons.com· 2 days agoPfizer reports first-quarter adjusted earnings of 82 cents a share on revenue of $14.88 billion.Read...
Pfizer: Q1 Earnings Snapshot
Midland Reporter-Telegram· 2 days agoNEW YORK (AP) — NEW YORK (AP) — Pfizer Inc. (PFE) on Wednesday reported first-quarter...
Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales
NBC Los Angeles· 2 days agoPfizer reported first-quarter revenue that beat expectations and hiked its full-year profit outlook,...
What's Going With Pfizer Stock On Wednesday? - Pfizer (NYSE:PFE)
Benzinga· 2 days agoOn Wednesday, Pfizer Inc. PFE reported first-quarter adjusted EPS of $0.82, down 33% year over year,...
Pfizer's first-quarter results top estimates, while drugmaker boosts full-year profit outlook
Morningstar· 2 days agoPfizer Inc. on Wednesday reported first-quarter profit and sales that beat analyst expectations and raised its full-year earnings guidance as cancer and heart-disease drugs ...
Pfizer reports dip in first quarter profits, yet beats estimates
dpa international via Yahoo Finance· 2 days agoThe US pharmaceutical giant Pfizer on Wednesday said its earnings for the first quarter had declined...
Pfizer Inc. (PFE): A New Perspective – Stocks Register
Stocks Register· 1 day agoPfizer Inc. (NYSE:PFE) concluded the trading at $27.18 on Wednesday, May 01, with a rise of 6.09% from its closing price on previous day. Taking a look at stock we notice ...
Pfizer to pay $25.5 mln to settle remaining Effexor XR antitrust claims
Reuters· 4 days agoPfizer has agreed to pay $25.5 million to resolve claims that its predecessor Wyeth conspired with...
Pfizer Reportedly Plans D2C COVID and Migraine Drug Platform
PYMNTS.com· 2 days agoPharmaceutical giant Pfizer is reportedly creating an online platform selling anti-COVID and...
Pfizer plans to be 'very active' in obesity market, but CEO mum on precise R&D plans
FierceBiotech· 2 days agoPfizer’s 2024 revival tour is off and running, but the Big Pharma remains mum on one critical...